Roivant Sciences (ROIV) Stock Forecast & Price Target

Compare

655 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ROIV Analyst Ratings

Strong Buy

7 Buy

2 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Roivant

Sciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ROIV Stock 12 Month Forecast

Average Price Target

$15.71

▲(31.35% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Roivant Sciences in the last 3 months. The average price target is $15.71 with a high forecast of $19.00 and a low forecast of $12.00. The average price target represents a 31.35% change from the last price of $11.96.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","11":"$11","14":"$14","17":"$17","20":"$20"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$19.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,11,14,17,20],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.31,11.901538461538461,12.493076923076924,13.084615384615384,13.676153846153847,14.267692307692307,14.85923076923077,15.45076923076923,16.04230769230769,16.633846153846154,17.225384615384616,17.816923076923075,18.408461538461538,{"y":19,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.31,11.64846153846154,11.986923076923077,12.325384615384616,12.663846153846155,13.002307692307692,13.340769230769231,13.67923076923077,14.017692307692307,14.356153846153846,14.694615384615386,15.033076923076923,15.371538461538462,{"y":15.71,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.31,11.363076923076923,11.416153846153847,11.46923076923077,11.522307692307693,11.575384615384616,11.628461538461538,11.681538461538462,11.734615384615385,11.787692307692307,11.840769230769231,11.893846153846154,11.946923076923078,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.83,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.62,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.23,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.68,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.48,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.83,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.13,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.74,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.85,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.58,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.17,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.94,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.31,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$19.00

Average Price Target$15.71

Lowest Price Target$12.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Dex Genotek

TR | OpenAI - 4o

$11.5→$12

Hold

0.33%

Upside

Reiterated

08/13/25

AI Generated ArticleAI Generated Article

Douglas Tsao

H.C. Wainwright

$18

Buy

50.50%

Upside

Reiterated

08/12/25

Promising Potential of Roivant Sciences' Brepocitinib and Pipeline Fuels Buy Rating

David Risinger

Leerink Partners

$17→$18

Buy

50.50%

Upside

Reiterated

08/12/25

Leerink Partners Keeps Their Buy Rating on Roivant Sciences (ROIV)

Yaron Werber

TD Cowen

―

Buy

―

Reiterated

08/11/25

TD Cowen Keeps Their Buy Rating on Roivant Sciences (ROIV)We like risk/reward and see stock moving +20-25%. Ph2 CS (H2:26) and Ph3 NIU (H1:27) enrolling rapidly. $1.5B in stock buybacks completed.

Yatin Suneja

Guggenheim

$15

Buy

25.42%

Upside

Reiterated

08/11/25

Guggenheim Sticks to Its Buy Rating for Roivant Sciences (ROIV)

Chi Meng Fong

Bank of America Securities

$12

Hold

0.33%

Upside

Reiterated

08/11/25

Bank of America Securities Sticks to Their Hold Rating for Roivant Sciences (ROIV)

Brian Cheng

J.P. Morgan

$16

Buy

33.78%

Upside

Assigned

07/25/25

Roivant Sciences placed on 'Positive Catalyst Watch' at JPMorganRoivant Sciences placed on 'Positive Catalyst Watch' at JPMorgan

Corinne Johnson

Goldman Sachs

$19

Buy

58.86%

Upside

Initiated

07/10/25

Roivant Sciences (ROIV) Initiated with a Buy at Goldman Sachs

Prakhar Agrawal

Cantor Fitzgerald

―

Buy

―

Reiterated

06/18/25

Cantor Fitzgerald Sticks to Their Buy Rating for Roivant Sciences (ROIV)

Dennis Ding

Jefferies

$18

Buy

50.50%

Upside

Reiterated

03/11/25

Strategic Growth Potential in Roivant Sciences: Capitalizing on Graves' Disease Market and FcRn Indications

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Dex Genotek

TR | OpenAI - 4o

$11.5→$12

Hold

0.33%

Upside

Reiterated

08/13/25

AI Generated ArticleAI Generated Article

Douglas Tsao

H.C. Wainwright

$18

Buy

50.50%

Upside

Reiterated

08/12/25

Promising Potential of Roivant Sciences' Brepocitinib and Pipeline Fuels Buy Rating

David Risinger

Leerink Partners

$17→$18

Buy

50.50%

Upside

Reiterated

08/12/25

Leerink Partners Keeps Their Buy Rating on Roivant Sciences (ROIV)

Yaron Werber

TD Cowen

―

Buy

―

Reiterated

08/11/25

TD Cowen Keeps Their Buy Rating on Roivant Sciences (ROIV)We like risk/reward and see stock moving +20-25%. Ph2 CS (H2:26) and Ph3 NIU (H1:27) enrolling rapidly. $1.5B in stock buybacks completed.

Yatin Suneja

Guggenheim

$15

Buy

25.42%

Upside

Reiterated

08/11/25

Guggenheim Sticks to Its Buy Rating for Roivant Sciences (ROIV)

Chi Meng Fong

Bank of America Securities

$12

Hold

0.33%

Upside

Reiterated

08/11/25

Bank of America Securities Sticks to Their Hold Rating for Roivant Sciences (ROIV)

Brian Cheng

J.P. Morgan

$16

Buy

33.78%

Upside

Assigned

07/25/25

Roivant Sciences placed on 'Positive Catalyst Watch' at JPMorganRoivant Sciences placed on 'Positive Catalyst Watch' at JPMorgan

Corinne Johnson

Goldman Sachs

$19

Buy

58.86%

Upside

Initiated

07/10/25

Roivant Sciences (ROIV) Initiated with a Buy at Goldman Sachs

Prakhar Agrawal

Cantor Fitzgerald

―

Buy

―

Reiterated

06/18/25

Cantor Fitzgerald Sticks to Their Buy Rating for Roivant Sciences (ROIV)

Dennis Ding

Jefferies

$18

Buy

50.50%

Upside

Reiterated

03/11/25

Strategic Growth Potential in Roivant Sciences: Capitalizing on Graves' Disease Market and FcRn Indications

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Roivant Sciences

1 Month

xxx

Success Rate

20/33 ratings generated profit

Average Return

+4.58%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 60.61% of your transactions generating a profit, with an average return of +4.58% per trade.

3 Months

xxx

Success Rate

17/25 ratings generated profit

Average Return

+13.72%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 68.00% of your transactions generating a profit, with an average return of +13.72% per trade.

1 Year

Douglas TsaoH.C. Wainwright

Success Rate

21/25 ratings generated profit

Average Return

+42.52%

reiterated a buy rating 4 days ago

Copying Douglas Tsao's trades and holding each position for 1 Year would result in 84.00% of your transactions generating a profit, with an average return of +42.52% per trade.

2 Years

xxx

Success Rate

23/25 ratings generated profit

Average Return

+48.21%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 92.00% of your transactions generating a profit, with an average return of +48.21% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ROIV Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ROIV has received 14 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. ROIV average Analyst price target in the past 3 months is 15.71.

Each month's total comprises the sum of three months' worth of ratings.

ROIV Financial Forecast

ROIV Earnings Forecast

Next quarter’s earnings estimate for ROIV is -$0.31 with a range of -$0.47 to -$0.25. The previous quarter’s EPS was -$0.25. ROIV beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.26% of the time in the same period. In the last calendar year ROIV has Outperformed its overall industry.

ROIV Sales Forecast

Next quarter’s sales forecast for ROIV is $6.31M with a range of $1.78M to $15.00M. The previous quarter’s sales results were $2.17M. ROIV beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.59% of the time in the same period. In the last calendar year ROIV has Outperformed its overall industry.

ROIV Stock Forecast FAQ

What is ROIV’s average 12-month price target, according to analysts?

Based on analyst ratings, Roivant Sciences’s 12-month average price target is 15.71.

What is ROIV’s upside potential, based on the analysts’ average price target?

Roivant Sciences has 31.35% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ROIV a Buy, Sell or Hold?

Roivant Sciences has a consensus rating of Strong Buy which is based on 7 buy ratings, 2 hold ratings and 0 sell ratings.

What is Roivant Sciences’s price target?

The average price target for Roivant Sciences is 15.71. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $19.00 ,the lowest forecast is $12.00. The average price target represents 31.35% Increase from the current price of $11.96.

What do analysts say about Roivant Sciences?

Roivant Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of ROIV?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Roivant Sciences (ROIV) Stock Forecast & Price Target

ROIV Analyst Ratings

ROIV Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Roivant Sciences

ROIV Analyst Recommendation Trends

ROIV Financial Forecast

ROIV Earnings Forecast

ROIV Sales Forecast

ROIV Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts